Effective treatment of post-spinal fusion methicillin-resistant  vertebral osteomyelitis with linezolid in a renal-transplant patient by unknown
Yunde et al. BMC Res Notes  (2015) 8:708 
DOI 10.1186/s13104-015-1694-7
CASE REPORT
Effective treatment of post-spinal fusion 
methicillin-resistant Staphylococcus aureus 
vertebral osteomyelitis with linezolid  
in a renal-transplant patient
Atsushi Yunde1, Kazuhide Inage1* , Sumihisa Orita1, Kazuyo Yamauchi1, Miyako Suzuki1, Yoshihiro Sakuma2, 
Go Kubota1, Yasuhiro Oikawa3, Takeshi Sainoh1, Jun Sato1, Kazuki Fujimoto1, Yasuhiro Shiga1, Koki Abe1, 
Hirohito Kanamoto1, Takane Suzuki4, Kazuhisa Takahashi1 and Seiji Ohtori1
Abstract 
Background: Methicillin-resistant Staphylococcus aureus (MRSA)-caused pyogenic spondylitis is a serious complica-
tion associated with lumbar fusion surgery. Often, anti-MRSA drugs are not used properly or patients discontinue 
drug use because of side effects including renal failure.
Case presentation: We report a case at our hospital of a 54-year-old male renal-transplant patient who developed 
MRSA vertebral osteomyelitis after spinal fusion and was treated effectively with linezolid. After diagnosis of post–
fusion surgery osteomyelitis, we conducted emergency flushing and debridement and began linezolid treatment 
(1200 mg/day, divided) immediately after the surgery. The level of C-reactive protein gradually decreased and became 
negative 4 weeks after the initiation of linezolid treatment. Serum creatinine level was approximately 1.3 mg/dL 
throughout the treatment period, indicating no deterioration in renal function.
Conclusion: These results suggest that early flushing and debridement together with linezolid administration is an 
effective treatment for MRSA vertebral osteomyelitis in renal-transplant patients.
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Background
The use of implants is common in orthopedic surgery 
but may predispose to postoperative infection, which is a 
refractory and severe complication. Methicillin-resistant 
Staphylococcus aureus (MRSA) vertebral osteomyelitis 
is a common infection associated with surgical implants, 
and is generally treated with anti-MRSA drugs. However, 
treatment of this disease is difficult because anti-MRSA 
drugs have poor tissue penetration and are often misused 
or discontinued because of renal dysfunction, a common 
side effect. By contrast, linezolid is an anti-MRSA drug 
with superior tissue penetration that has been shown 
to be an effective therapy for MRSA osteomyelitis [1]. 
Furthermore, the pharmacokinetics of linezolid are not 
influenced by renal dysfunction [2]. Here, we report a 
case at our hospital of effective linezolid treatment in a 
renal-transplant patient with post-spinal fusion MRSA 
vertebral osteomyelitis.
Case presentation
A 54-year-old man, who had undergone continuous 
artificial dialysis for the previous 20  years because of 
nephronophthisis, underwent a renal transplant at our 
hospital. After the transplant, he was treated with an 
immunosuppressive drug (Prograf; 1  mg/day) and a 
steroid (Predonine; 5  mg/day). The patient was subse-
quently diagnosed with lumbar spinal-canal stenosis, and 
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strongly requested surgical treatment because of poor 
quality of life, including lower back pain and intermittent 
claudication occurring approximately every 5  min. We 
performed an L3/4 lumbar posterior decompression and 
posterior lumbar interbody fusion (with use of autog-
enous bone). The lower back pain was improved after the 
surgery, but the patient developed a fever 1  week after 
the surgery. An intensity change in a magnetic resonance 
imaging (MRI) scan was recognized within the L3/4 
intervertebral disk (Fig.  1). An extensive subcutaneous 
hematoma, which extended into a deep surgical site, was 
identified. A lumbar puncture of this site was positive 
for MRSA-positive on bacterial culture, and the patient 
was diagnosed with post-spinal fusion MRSA vertebral 
osteomyelitis. At the same time, we checked the linezolid 
sensitivity, which was positive, and MIC. And it was posi-
tive. We therefore performed emergency flushing and 
debridement and began linezolid treatment (1200  mg/
day, divided) immediately after the surgery. However, we 
did not opt to remove the pedicle screw inserted previ-
ously for the purpose of fixation because of the risk of 
secondary osteoporosis due to long-term systemic use of 
a steroid.
Throughout the course of linezolid treatment, the 
C-reactive protein (CRP) level gradually decreased, 
becoming negative 4  weeks after administration started 
(Fig.  2). Serum creatinine (Cr) concentration was 
approximately 1.3  mg/dL during the treatment period, 
indicating no deterioration in renal function (Fig.  3). 
Hemoglobin (Hb) level decreased from approximately 
10–6 g/dL within 2 weeks of starting linezolid treatment 
(Fig. 4), suggesting the development of bone marrow sup-
pression. Fortunately, the infection had been stabilized 
by early treatment with antibiotics, and linezolid was 
replaced with a trimethoprim–sulfamethoxazole (TMP–
SMZ) combination (320  mg TMP and 1600  mg SMZ) 
until the Hb level recovered, at which point linezolid use 
was re-instated. However, we did not administer a pre-
ventative antibiotic after the patient tested CRP-negative 
because of the risk of renal damage. Fortunately, infec-
tion has not recurred up to the present time (3 years after 
the operation).
Discussion
In many cases of postoperative infection involving surgi-
cal implants, it is difficult to remove the implant. Accord-
ing to the guidelines for implant-related MRSA infection 
published by the Infectious Diseases Society of America 
(IDSA), use of anti-MRSA drugs is acceptable without 
removal of the implant only in the case of infection devel-
opment within 2 months after surgery, implant stability, 
or sufficient debridement within 3 weeks after the devel-
opment of infection [3]. In the present case, early flushing 
and debridement together with linezolid administration 
was performed to suppress the infection while maintain-
ing the implant. The present case is particularly relevant 
for secondary osteoporosis patients with long-term sys-
temic use of a steroid. This treatment modality could be 
used to avoid the risk of aggravation and vertebral insta-
bility that comes with removing an implant.
In the present case, we selected linezolid because of its 
superior tissue penetration and low risk of renal compli-
cations. The linezolid in  vivo utilization rate in relation 
to tissue penetration is approximately 100 %, and because 
linezolid also maintains a good tissue penetration with 
high water solubility, levels of the drug can reach high 
concentrations in the bone or cerebrospinal fluid, areas 
known for poor drug penetration [4, 5]. In the present 
Fig. 1 Magnetic resonance imaging of the lumbar spine pre- and post-surgery
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case, the infection had deeply penetrated the site and the 
CRP level was 12.5  mg/dL before the start of linezolid 
administration. CRP level gradually decreased after the 
initiation of linezolid treatment and eventually became 
negative 4  weeks following initial treatment. This sug-
gests that linezolid exhibited high tissue penetration. 
Linezolid is primarily excreted in the urine through 
its principal metabolites, aminoethoxyacetic acid and 
hydroxyethyl glycine. The pharmacokinetics of linezolid 
are not influenced by deterioration of renal function or 
moderate deterioration of hepatic function, and therefore 
dose adjustments are not necessary even in the case of 
renal dysfunction [2]. The present case suggests that lin-
ezolid is a valid treatment option because it did not result 
in deterioration of renal function. However, because 
some reports describe an increased risk of thrombocyto-
penia in cases of prolonged linezolid use in patients with 
deterioration of renal function, patients with renal dys-
function who receive linezolid need to be closely moni-
tored [6].
A common side effect of linezolid use is pancytope-
nia, caused by bone marrow suppression. Frequency of 
pancytopenia is significantly increased when linezolid 
is administered for more than 2  weeks [5]. In cases of 
pancytopenia, dose reduction or withdrawal of linezolid 
may be considered, but may be problematic because of 
the risk of reinfection. In our hospital, dose reduction 
or withdrawal of linezolid is considered in patients with 
an Hb level of ≤6.0 g/dL, but if this does not adequately 
treat the pancytopenia, blood transfusion therapy is an 
option. Furthermore, according to previous reports, 
platelet transfusion can be used to treat thrombocy-
topenia [7]. A decline in Hb level was detected 2 weeks 
after the start of administration of linezolid in the pre-
sent case, but because the development of infection had 
been stabilized, we treated the symptoms by switching 
treatment from linezolid to a TMP–SMZ combination. 
These results suggest that early flushing and debride-
ment together with linezolid administration is an effec-
tive treatment for post-spinal fusion MRSA vertebral 
osteomyelitis.
Conclusion
We describe a renal-transplant patient with post-spinal 
fusion MRSA vertebral osteomyelitis in whom infection 
was suppressed without deterioration of renal function 
by early flushing and debridement together with linezolid 
administration.
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Fig. 2 Changes in the serum C-reactive protein (CRP) level
Fig. 3 Changes in the serum creatinine (Cr) level
Fig. 4 Changes in the serum hemoglobin (Hb) level
Page 4 of 4Yunde et al. BMC Res Notes  (2015) 8:708 
Authors’ contributions
AY, KY, MS, YoS, GK, YO, TakeS, JS, KF, YaS, KA, HK, TakaS and KT analyzed and 
interpreted the patient data. KI, SuO and SeO performed the corrective sur-
gery surgery. AY, KI, KY, SuO, MS, TakaS, KT and SeO were major contributors in 
writing the manuscript. All authors read and approved the final manuscript.
Author details
1 Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba 
University, 1-8-1 Inohana Chuo-ku, Chiba City, Chiba 260-8670, Japan. 
2 Department of Orthopaedic Surgery, National Hospital Organization, Chiba 
Medical Center, Chiba, Japan. 3 Department of Orthopaedic Surgery, Chiba 
Children’s Hospital, Chiba, Japan. 4 Department of Bioenvironmental Medicine, 
Graduate School of Medicine, Chiba University, Chiba, Japan. 
Acknowledgements
We would like to thank the staff and management at the Department of 
Orthopaedic Surgery, Graduate School of Medicine Chiba University. All of the 
authors, has no fund to declare in the present case.
Competing interests
The authors declare that they have no competing interests.
Received: 2 October 2015   Accepted: 13 November 2015
References
 1. Gaudin A, Jacqueline C, Gautier H, Desessard C, Le Mabecque V, 
Miegeville AF, et al. A delivery system of linezolid to enhance the MRSA 
osteomyelitis prognosis: in vivo experimental assessment. Eur J Clin 
Microbiol Infect Dis. 2013;32:195–8.
 2. Brier ME, Ray PC, Klein JB. Prediction of delayed renal allograft func-
tion using an artificial neural network. Nephrol Dial Transplant. 
2003;18:2655–9.
 3. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical 
practice guidelines by the Infectious Diseases Society of America for the 
treatment of methicillin-resistant Staphylococcus aureus infections in 
adults and children. Clin Infect Dis. 2011;52:e18–55.
 4. Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency 
of linezolid-associated thrombocytopenia and anemia among patients 
with end-stage renal disease. Clin Infect Dis. 2006;42:66–72.
 5. Soriano A, Ortega M, García S, Peñarroja G, Bové A, Marcos M, et al. 
Comparative study of the effects of pyridoxine, rifampin, and renal func-
tion on hematological adverse events induced by linezolid. Antimicrob 
Agents Chemother. 2007;51:2559–63.
 6. Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, et al. High frequency of 
linezolid-associated thrombocytopenia among patients with renal insuf-
ficiency. lnt J Antimicrob Agents. 2006;28:345–51.
 7. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. 
Risk factors associated with the development of thrombocytope-
nia in patients who received linezolid therapy. J Infect Chemother. 
2011;17:382–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
